Legend Biotech Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 96.01 million compared to USD 27.36 million a year ago. Net loss was USD 62.21 million compared to USD 84.96 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to USD 0.52 a year ago. Diluted loss per share from continuing operations was USD 0.34 compared to USD 0.52 a year ago.
For the nine months, revenue was USD 205.68 million compared to USD 89.37 million a year ago. Net loss was USD 373.44 million compared to USD 310.47 million a year ago. Basic loss per share from continuing operations was USD 2.14 compared to USD 1.98 a year ago. Diluted loss per share from continuing operations was USD 2.14 compared to USD 1.98 a year ago.